Dogwood Wealth Management’s Standard BioTools LAB Stock Holding History

Dogwood Wealth Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27	Closed	-$25	–	892
2026 Q1	$25	Hold	27	–	–	﹤0.01%	853
2025 Q4	$35	Hold	27	–	–	﹤0.01%	732
2025 Q3	$35	Hold	27	–	–	﹤0.01%	736
2025 Q2	$35	Hold	27	–	–	﹤0.01%	682
2025 Q1	$29	Hold	27	–	–	﹤0.01%	526
2024 Q4	$47	Buy	+27	New	+$50	﹤0.01%	270

Other funds holding LAB

MAM

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Dogwood Wealth Management's LAB Position: Q2 2026 in Review

Dogwood Wealth Management sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 27 shares — an estimated $25 sold.

Dogwood Wealth Management first reported a position in LAB in Q4 2024 and held it in 6 quarters. The position peaked at $47 in Q4 2024. 5 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Dogwood Wealth Management reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
Dogwood Wealth Management sold 27 Standard BioTools shares in Q2 2026, an estimated $25.
Dogwood Wealth Management first reported a position in Standard BioTools in Q4 2024 and held it in 6 quarters.
Dogwood Wealth Management's Standard BioTools position peaked at $47 in Q4 2024.
5 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Dogwood Wealth Management's 13F filing for Q2 2026, filed 6 Jul 2026.